BACKGROUND: It remains unclear whether primary tumor resection benefits patients with metastatic neuroblastoma. The authors assessed the impact of extent and timing of resection on outcome in these patients. METHODS: The authors reviewed the records of 124 patients > 1 year of age at diagnosis of International Neuroblastoma Staging System Stage 4 neuroblastoma. The survival estimates of those who did and did not have a gross total resection (GTR) and of those who had initial versus delayed GTR were compared. Surgical complications were reviewed. RESULTS: The 5-year survival estimates were comparable for the 90 patients who had a GTR and the 17 who underwent surgery but did not have a GTR (29.9% +/- 5.1% [standard error] vs. 29.4% +/- 10.1%). The 7 patients who underwent GTR at the time of diagnosis had a higher 5-year survival estimate than the 83 patients who had a GTR after induction chemotherapy (83.3% +/- 13.9% vs. 25.2% +/- 5.0%) (P = 0.001). Five-year event-free survival estimates were similarly higher in the initial-GTR group (57.1% +/- 18.7% vs. 14.5% +/- 4.2%) (P = 0.002). These two groups did not differ significantly in age at diagnosis (P = 0.118), site of primary tumor (P = 0.34), MYCN amplification status (P = 1), serum lactate dehydrogenase activity at diagnosis (P = 0.34), or treatment protocol (P = 0.22). Twenty-two (21%) patients had a surgical complication. CONCLUSIONS: In this small cohort of patients with metastatic neuroblastoma, GTR at the time of diagnosis offered a survival benefit. Further prospective studies are warranted before this approach can be applied to all patients with metastatic neuroblastoma. Copyright 2005 American Cancer Society.
BACKGROUND: It remains unclear whether primary tumor resection benefits patients with metastatic neuroblastoma. The authors assessed the impact of extent and timing of resection on outcome in these patients. METHODS: The authors reviewed the records of 124 patients > 1 year of age at diagnosis of International Neuroblastoma Staging System Stage 4 neuroblastoma. The survival estimates of those who did and did not have a gross total resection (GTR) and of those who had initial versus delayed GTR were compared. Surgical complications were reviewed. RESULTS: The 5-year survival estimates were comparable for the 90 patients who had a GTR and the 17 who underwent surgery but did not have a GTR (29.9% +/- 5.1% [standard error] vs. 29.4% +/- 10.1%). The 7 patients who underwent GTR at the time of diagnosis had a higher 5-year survival estimate than the 83 patients who had a GTR after induction chemotherapy (83.3% +/- 13.9% vs. 25.2% +/- 5.0%) (P = 0.001). Five-year event-free survival estimates were similarly higher in the initial-GTR group (57.1% +/- 18.7% vs. 14.5% +/- 4.2%) (P = 0.002). These two groups did not differ significantly in age at diagnosis (P = 0.118), site of primary tumor (P = 0.34), MYCN amplification status (P = 1), serum lactate dehydrogenase activity at diagnosis (P = 0.34), or treatment protocol (P = 0.22). Twenty-two (21%) patients had a surgical complication. CONCLUSIONS: In this small cohort of patients with metastatic neuroblastoma, GTR at the time of diagnosis offered a survival benefit. Further prospective studies are warranted before this approach can be applied to all patients with metastatic neuroblastoma. Copyright 2005 American Cancer Society.
Authors: Jared R Robbins; Matthew J Krasin; Atmaram S Pai Panandiker; Amy Watkins; Jianrong Wu; Victor M Santana; Wayne L Furman; Andrew M Davidoff; Lisa M McGregor Journal: J Pediatr Surg Date: 2010-04 Impact factor: 2.545
Authors: Maria Antonietta De Ioris; Alessandro Crocoli; Benedetta Contoli; Maria Carmen Garganese; Gianluigi Natali; Paolo Tomà; Alessandro Jenkner; Renata Boldrini; Maria Debora De Pasquale; Giuseppe Maria Milano; Silvia Madafferi; Aurora Castellano; Franco Locatelli; Alessandro Inserra Journal: BMC Cancer Date: 2015-02-21 Impact factor: 4.430
Authors: Janina Fischer; Alexandra Pohl; Ruth Volland; Barbara Hero; Martin Dübbers; Grigore Cernaianu; Frank Berthold; Dietrich von Schweinitz; Thorsten Simon Journal: BMC Cancer Date: 2017-08-04 Impact factor: 4.430
Authors: Asad Ullah; Atbin Doroodchi; Luis Velasquez Zarate; Samantha N Mattox; Taylor Sliker; Dorian K Willhite; Jaffar Khan; Harry C Owen; Surendra K Rajpurohit; Nikhil G Patel; Robyn M Hatley Journal: Int J Environ Res Public Health Date: 2021-04-14 Impact factor: 3.390
Authors: John Thomas Lucas; Daniel Victor Wakefield; Michael Doubrovin; Yimei Li; Teresa Santiago; Sara Michele Federico; Thomas E Merchant; Andrew M Davidoff; Matthew J Krasin; Barry L Shulkin; Victor M Santana; Wayne Lee Furman Journal: Clin Transl Radiat Oncol Date: 2022-03-10